Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease
Beatriz Serrano(Institut d'Investigació Biomédica de Bellvitge), Silvia de Sanjosé(Barcelona Institute for Global Health), Thomas Weiß(Merck & Co., Inc., Rahway, NJ, USA (United States)), Gary M. Clifford(Centre international de recherche sur le cancer), Laia Bruni(Institut d'Investigació Biomédica de Bellvitge), Laia Alemany, Sara Tous(Institut d'Investigació Biomédica de Bellvitge), F. Xavier Bosch(Vall d'Hebron Hospital Universitari)
Cited by 304
Related Papers
Prevalence of Human Papillomavirus in Cervical Cancer: a Worldwide Perspective
|JNCI Journal of the National Cancer Institute|1995|3.4k
Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis
|The Lancet Global Health|2019|2.4k
Human Papillomavirus Types in Head and Neck Squamous Cell Carcinomas Worldwide: A Systematic Review
|Cancer Epidemiology Biomarkers & Prevention|2005|2.2k
Human papillomavirus type distribution in invasive cervical cancer and high‐grade cervical lesions: A meta‐analysis update
|International Journal of Cancer|2007|1.7k
Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis
|The Lancet Infectious Diseases|2007|1.7k